Clinical Trial Update: Retapamulin as a Decolonizing Agent for MRSA [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated retapamulin as a decolonizing agent for MRSA; the study is completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Methicillin-resistant Staphylococcus Aureus Infection

Drugs mentioned

• Retapamulin (retapamulin)

Snippet

Sponsor: NYU Langone Health | Conditions: MRSA | Phase 3 | Status: COMPLETED | Results posted: 2020-03-19